Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets slip
Wed, 10 Apr 01:30 pm

Indian share markets pared initial gains and slipped below the dotted line in the post-noon trading session. Majority of the sectoral indices are trading negative with FMCG , metal and realty stocks being the major losers. Only IT and banking stocks are trading in the green.

BSE-Sensex is down 6 points and NSE-Nifty is trading down 12 points. While BSE Mid Cap is down 0.5%, BSE Small Cap index is trading down by 0.3%. The rupee is trading at 54.5 to the US dollar.

FMCG stocks are trading mixed with Godrej Consumer and Jyothy Consumer being among the biggest gainers. However, Marico and Hindustan Unilever (HUL) are among the leading losers. As per a leading financial daily, FMCG companies are resorting to price cuts, discounts and promotions to pull out of demand slowdown as consumers cut back on their disposable spends. Companies like Hindustan Unilever , ITC, Procter & Gamble, Cadbury and Heinz have announced discounts ranging between 10%-70% on premium products in the past two weeks. HUL has reduced the price of its premium soaps Dove and Pears by Rs 5. US food-major Heinz is offering Rs 20 off on Complan milk drink. Cadbury has slashed Rs 100 on 200-gm bars of its chocolate brand Toblerone whereas Heinz has reduced the price of its Complan milk drink by Rs 20. Even popular brands such as Godrej Consumer Products' Godrej No.1 and HUL's Lux have been discounted by 5%-10%. After raising prices in the past year to maintain sales momentum, slowdown in offtake is compelling companies to go in the reverse gear.

Most of the Indian pharma stocks are trading mixed with Lupin Ltd and Elder Pharma being the leading gainers, while Ipca Laboratories and Torrent Pharma are the top losers. Dr Reddy's has announced that the company plans to relocate its North American headquarters and establish R&D centre in Princeton, New Jersey. Dr Reddy's has entered into lease contract with the National business parks on the said locations. The new setup will employ 300 plus people, as the company expects growth in its US business for the upcoming period. The R&D facility will also employ approx. 35 scientists, chemists and support personal. Both the ventures are expected to be completed in 2013. Reportedly, as per GV Prasad - chairman and CEO of the company, the relocation will help the company tap the local talent which will help in growth of the US business. Apart from this, the establishment of the R&D centre along with other centres establishes the company's presence within some leading R&D centres globally. The stock of Dr Reddy was trading up by 0.2%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets slip". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.